Centiva Capital LP Takes Position in Bausch + Lomb Co. (NYSE:BLCO)

Centiva Capital LP purchased a new stake in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 25,000 shares of the company's stock, valued at approximately $452,000.

Several other hedge funds have also bought and sold shares of BLCO. Barclays PLC purchased a new position in shares of Bausch + Lomb in the third quarter valued at about $5,797,000. FNY Investment Advisers LLC purchased a new position in shares of Bausch + Lomb in the fourth quarter valued at about $72,000. Ellsworth Advisors LLC purchased a new position in shares of Bausch + Lomb in the fourth quarter valued at about $665,000. Blue Trust Inc. lifted its position in shares of Bausch + Lomb by 68.3% in the fourth quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock valued at $48,000 after acquiring an additional 1,004 shares in the last quarter. Finally, Renaissance Capital LLC lifted its position in shares of Bausch + Lomb by 116.2% in the fourth quarter. Renaissance Capital LLC now owns 94,182 shares of the company's stock valued at $1,701,000 after acquiring an additional 50,622 shares in the last quarter. Institutional investors own 11.07% of the company's stock.

Bausch + Lomb Trading Down 0.1%

Bausch + Lomb stock traded down $0.01 during trading on Friday, reaching $11.79. 97,638 shares of the company were exchanged, compared to its average volume of 656,836. Bausch + Lomb Co. has a 52-week low of $10.45 and a 52-week high of $21.69. The company has a market capitalization of $4.17 billion, a P/E ratio of -12.96, a PEG ratio of 0.85 and a beta of 0.58. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.60 and a quick ratio of 1.01. The stock's 50 day simple moving average is $13.11 and its two-hundred day simple moving average is $16.35.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.10). The business had revenue of $1.15 billion during the quarter, compared to analysts' expectations of $1.15 billion. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. Bausch + Lomb's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.07 EPS. On average, equities research analysts expect that Bausch + Lomb Co. will post 0.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on BLCO. Bank of America decreased their target price on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating on the stock in a research report on Thursday, February 20th. Citigroup decreased their target price on Bausch + Lomb from $14.00 to $13.00 and set a "neutral" rating on the stock in a research report on Thursday, May 1st. HC Wainwright decreased their target price on Bausch + Lomb from $20.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Morgan Stanley reduced their price objective on Bausch + Lomb from $18.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, Evercore ISI cut their target price on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating on the stock in a research note on Thursday, May 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, Bausch + Lomb has a consensus rating of "Hold" and a consensus target price of $15.50.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.